Keywords ALK, biomarkers, chemotherapy, cisplatin, EGFR, immune checkpoint inhibition, PD-1, pemetrexed Summary of Key Points • The determination of tumor histology in nonsmall cell lung cancer (NSCLC) has become…
Summary of Key Points • There are a growing proportion of patients who are candidates for second-line therapy and beyond. • Treatment choices are dictated by tumor histology, molecular phenotype…
Summary of Key Points • Treatment of lung cancer is rapidly evolving. Large cell carcinomas as a group have therapeutically relevant driver mutations in nearly 40% of cases. • Despite…
Summary of Key Points • Immunotherapy has entered a new era in lung cancer and is rapidly changing the standard of care. • Vaccines as monotherapies have shown marginal efficacy…
Summary of Key Points • Radiation-induced brachial plexopathy (RIBP) occurs with treatment of apical tumors and is frequently complicated by tumor-related brachial plexopathy (TRBP). Stereotactic ablative radiotherapy (SABR) of apical…
Abstract Clinical trials for lung cancer are needed to investigate new treatment or preventative options and to improve outcomes for patients with lung cancer. Times are changing; clinical researchers now…
Summary of Key Points • Development of malignant mesothelioma is usually associated with asbestos exposure. • The most common genetic alterations in mesothelioma are deletion of CDKN2A/ARF , inactivation of…
Abstract This chapter discusses first-line and second-line therapy for patients with extensive-stage small cell lung cancer (ED SCLC). As first-line therapy, a platinum agent plus etoposide or irinotecan remains the…
Summary of Key Points • Lung cancer is increasingly understood at the molecular level; N-of-1 trials are becoming more relevant with the use of biomarker assessment and targeted therapies. •…
Summary of Key Points • The best palliative outcomes are obtained when palliative care is involved early in advanced lung cancer. • Integration of palliative care early in the advanced…
